GSK and LTZ collaborate to advance novel myeloid cell engagers in oncology

ChristianaCare launches Organoid Core to personalize cancer treatment

ChristianaCare’s Cawley Center for Translational Cancer Research has established an organoid core.

November 21, 2025

CPRIT set to surpass $4B in grants

The governing board of the Cancer Prevention and Research Institute of Texas met in Austin on Nov. 19 and approved 73 grants totaling almost $154 million.

November 21, 2025

Vol.51 No.43

Drugs & Targets

Freenome and Roche to expand collaboration to develop and commercialize cancer screening tests outside the U.S.

Freenome, an early cancer detection company, and Roche announced a collaboration agreement to commercialize Freenome’s cancer screening technology in international markets.

November 21, 2025

Vol.51 No.43

Drugs & Targets

Microsoft and Qure.ai collaborate to accelerate AI lung cancer detection

Microsoft and Qure.ai announced a collaboration that will streamline deployment of Qure.ai solutions to hospitals and health systems across the U.S.

November 21, 2025

Vol.51 No.43

Advancing symptom science at City of Hope and across the globe

The landscape of cancer treatment is rapidly evolving. Increasingly, there is recognition that care must go beyond treating the disease itself—it must also address the whole person and the debilitating symptoms patients experience during and after treatment.

How a neuroendocrine cancer survivor fueled 20 years of research
NETRF celebrates 20 years, $40 million in research funding

This year marks the Neuroendocrine Tumor Research Foundation’s 20th anniversary. Established as the Caring for Carcinoid Foundation by Nancy Lindholm in 2005, NETRF has served as one of the few funding sources for neuroendocrine cancers since its inception.

November 14, 2025

Vol.51 No.42

GSK and LTZ collaborate to advance novel myeloid cell engagers in oncology

YOU MAY BE INTERESTED IN

ChristianaCare launches Organoid Core to personalize cancer treatment

CPRIT set to surpass $4B in grants

Freenome and Roche to expand collaboration to develop and commercialize cancer screening tests outside the U.S.

Microsoft and Qure.ai collaborate to accelerate AI lung cancer detection

Advancing symptom science at City of Hope and across the globe

How a neuroendocrine cancer survivor fueled 20 years of research
NETRF celebrates 20 years, $40 million in research funding

Renew today!

Subscriber content

Never miss an issue!

Login

GSK and LTZ collaborate to advance novel myeloid cell engagers in oncology

YOU MAY BE INTERESTED IN

ChristianaCare launches Organoid Core to personalize cancer treatment

CPRIT set to surpass $4B in grants

Freenome and Roche to expand collaboration to develop and commercialize cancer screening tests outside the U.S.

Microsoft and Qure.ai collaborate to accelerate AI lung cancer detection

Advancing symptom science at City of Hope and across the globe

How a neuroendocrine cancer survivor fueled 20 years of researchNETRF celebrates 20 years, $40 million in research funding

Never miss an issue!

Login

How a neuroendocrine cancer survivor fueled 20 years of research
NETRF celebrates 20 years, $40 million in research funding